LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Genetic Test Improves Ovarian Cancer Treatment

By LabMedica International staff writers
Posted on 12 Jan 2023
Image: The new genetic test helps to identify ovarian cancer patients who benefit from a new drug (Photo courtesy of Helsinki University Hospital)
Image: The new genetic test helps to identify ovarian cancer patients who benefit from a new drug (Photo courtesy of Helsinki University Hospital)

Ovarian cancer has the worst prognosis among all gynecological cancers due to delay in diagnosis as its symptoms are often minor and unclear. Of late, the new PARP inhibitors as maintenance treatment for ovarian cancer after surgery and cytostatic therapy in newly-diagnosed ovarian cancer have demonstrated excellent results. However, the therapy can also cause serious side-effects, making it vital to target it to only those patients who stand to benefit the most from the treatment. Now, a new genetic test can identify ovarian cancer patients who can benefit from PARP inhibitors.

The genetic test developed at the University of Helsinki (Helsinki, Finland) and Helsinki University Hospital (Helsinki, Finland) using machine learning can identify patients whose tumors carry certain gene defects that are typical of ovarian cancer. The lesions are caused by a deficiency in the homologous recombination DNA repair pathway (HRD). These tumor types are the ones that are sensitive to PARP inhibitors. Their study has shown that each cancer type is associated with different characteristics of the genetic lesions related to HRD. In fact, it was important to develop a test optimized for ovarian cancer in order to advance the precision of therapies for the cancer type.

“The genetic test helps to identify patients who do not benefit from the drug, thus avoiding unnecessary treatment and the adverse effects associated with the drug,” said Specialist Anniina Färkkilä from HUS Helsinki University Hospital. “This therapy can now be administered to as many as half of the patients with ovarian cancer.”

“Clinical trials have shown that patients with HRD tumors have a strong response to PARP inhibitors, while the response of other patients is poor,” added Doctoral Researcher Fernando Perez Villatoro from the University of Helsinki. “The gene test and the algorithms are now freely available, and can be used in clinical care and trials to guide the treatment of ovarian cancer.”

Related Links:
University of Helsinki 
Helsinki University Hospital 

New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more